By granting French diagnostics services provider Diaxonhit with an exclusive license to perform the multi-gene expression test AlloMap, XDx earlier this month took a major step toward growing the European market for its flagship product.

Since 2005, Brisbane, Calif.-based XDx has been marketing AlloMap in the US, where more than 25,000 patients have been tested to date. FDA-cleared AlloMap is a blood-based test that gauges the expression of 20 genes and yields a score of between zero and 40. XDx performs the test in the US through its CLIA certified lab.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.